TRANSFORMED FOLLICULAR LYMPHOMA
Clinical trials for TRANSFORMED FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: drug duo aims to shrink tumors and delay progression
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR T-Cell combo shows promise for tough lymphoma
Disease control OngoingThis early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seve…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for aggressive lymphoma: targeted combo shows promise in early trial
Disease control OngoingThis study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells primed with decitabine show promise for tough lymphoma
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…
Matched conditions: TRANSFORMED FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC